Global Pituitary Cancer Market - 2022-2029

Global Pituitary Cancer Market - 2022-2029

Market Overview

Pituitary Cancer Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 9.4% during the forecast period (2022-2029).

Pituitary cancer is characterized by abnormal growth in the pituitary gland. It affects the functioning of the pituitary gland and may cause an increased or decreased level of pituitary hormone secretions within the body. Small pituitary cancer treatment is accessible through noninvasive treatment or medicines. But a large pituitary cancer treatment is challenging to treat because of its complex nature.

Market Dynamics

The major driving forces are the rising incidence of pituitary cancers, increasing investments in research and development activities, growing technological advancements in pituitary cancer treatment, and increasing demand for non-invasive surgery.

The increasing burden of pituitary cancer and the growing clinical research activities drive global market growth.

Pituitary adenomas account for at least 10% to 15% of all tumors that develop within your skull; therefore, the growing cases of brain cancer fuel the global pituitary cancer market. For instance, according to the Global Cancer Observatory, in 2020, there were 308,102 new cases and about 251,329 deaths. Furthermore, the increasing international clinical research activities for pituitary tumors/adenomas drive global market growth. Such as, according to the ClinicalTrials.Gov, there are currently 4 international clinical trials active, namely a Study to allow access to Pasireotide for patients benefiting from Pasireotide treatment in Novartis-sponsored studies and estimated to be completed by June 2023 and a study to estimate the consequences of irradiation of the Sellar Region and Cavernous Sinus on the autobiographical memory, sponsored by University Hospital, Bordeaux. Furthermore, currently, there are 26 international studies for pituitary adenoma/tumor recruiting.

The costly cancer treatment is restraining global pituitary cancer growth.

However, the high treatment cost, lack of awareness, side effects, and stringent regulations may hamper the pituitary cancer market. Before and after surgery, the side effects of before and after surgery, like infection, bleeding, etc., may restrain the pituitary cancer market over the forecast period.

Industry analysis

The global pituitary cancer report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing, pipeline analysis Etc.

Segment Analysis

Radiotherapy is expected to have a greater grasp on the pituitary cancer market during the forecast period (2022-2029).

Radiotherapy is expected to boost the market over the period forecast. The radiation therapy segment is sub-segmented into gamma knife stereotactic radiosurgery, external beam radiation, proton beam therapy, etc. Radiation therapy techniques improve and let the doctors focus radiation more precisely on the tumors and limit the damage to nearby healthy tissues. For instance, the Samsung Medical Center has started a multicenter evaluation of the effect of upfront radiosurgery on pituitary adenoma (MERGE). It is currently in phase III, and the estimated study completion date is December 2022. Thus, the promising pipeline of the key players related to radiation therapy in pituitary cancer drives the market. Also, a study approved to estimate the Efficiency and Safety of Different Treatment Strategies in Adults With Pituitary Adenomas With Hypothalamic Involvement and a Prospective Study of Clinically Nonfunctioning Pituitary Adenomas is currently recruiting.

Geographical Analysis

North America is expected to command dominating the global pituitary cancer market.

North America dominated the global pituitary cancer market in 2021. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to the rising incidences of pituitary cancers, robust research & development practices and the growing advancements in the field of neurology. The increasing number of pituitary cancer cases is expected to boost the market. For instance, the American Cancer Society estimated that about 10,000 pituitary tumors are diagnosed yearly in the US. The majority of these tumors are benign pituitary adenomas. Very few pituitary tumors are cancers (carcinomas). Thus, the growing number of pituitary cancer cases is driving the market. Also, the presence of pituitary cancer treatment centers in the region is expected to boost the market. At the OHSU Northwest Pituitary Center, they treat more than 1,500 patients and do more than 100 surgeries in and around the pituitary gland from around the US. They also diagnose pituitary conditions, give more second opinions, and performs more pituitary procedures than any other medical center in the region.

Competitive Landscape

The major players operating in the global pituitary cancer market are Sigma-Aldrich, Varian Medical Systems, Elekta, Accuray Incorporated, Corcept Therapeutics, Crinetics Pharmaceuticals, and Cydan. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the pituitary cancer market globally. For instance, on September 7, 2022, Accuracy Incorporated partnered with Swiss-based Genolier Innovation Hub to bring medical and technological advances to patients faster. Also, on April 28, 2022, Varian partnered with Icon Group to advance patient-centric solutions.

Accuracy Incorporated

Overview:

Accuracy Incorporated is a leading company that develops, manufactures and sells radiotherapy systems for alternative cancer treatments. Accuracy is committed to innovative designing radiotherapy solutions. Accuracy was founded in 1990 and is headquartered in Sunnyvale, California, the United States, with manufacturing facilities in Madison, Wisconsin, Sunnyvale, California, and Chengdu, China, with regional offices in Hon kong, China, and Tokyo, Japan. Accuracy has around 14 subsidiaries spread across the globe.

Product Portfolio:

The product portfolio of Accuracy Incorporated for Pituitary Cancer has Radixact Treatment Delivery System, TomoTherapy System and CyberKnife S7 stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) system.

The global pituitary cancer report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.